EGFR and breast carcinoma: More recently, we discovered that disruption of the EGFR/ErbB2-dependent signalling by lapatinib and CP-724714, two inhibitors of the receptor tyrosine kinase (RTK), diminished the amplitude of the SOCE in breast cancer cells [28].